Frost & Sullivan Acknowledges that PKC's Biosensors are Expected to Become the New Industry Standard in Pathogen Testing

Bio-Medicine.Org

MOUNTAIN VIEW, Calif., Feb. 13, 2013 /PRNewswire/ -- Based on its recent analysis of the global biosensors market, Frost & Sullivan recognizes Pharmaco-Kinesis Corporation (PKC) with the 2013 Global Frost & Sullivan Award for New Product Innovation. The company has set a new standard in the biosensors market with its innovative, highly sensitive biosensor. This unique, multi-pathogen detection device utilizes electrochemical impedance spectroscopy (EIS) to detect pathogens such as E. coli 0157:H7 and the severe acute respiratory syndrome (SARS) virus. It offers higher sensitivity, accuracy, cost-savings. Other key advantages are its greater portability and reusability; and a shorter, less complex testing process than other biosensors in the market. This exhibits PKC's market expertise and technological excellence.

PKC biosensors' sample preparation is conducted in a controlled environment, which eliminates the possibility of contamination. Additionally, PKC biosensors require minimal human intervention and provide immediate, real-time pathogen detection. The product has a longer lifespan than similar solutions and can operate efficiently for more than five years with repeated use.

Unlike other pathogen test instruments that utilize test strips or incubators, PKC biosensors use a biosensor container with an electrochemical sensor attached to the base, along with a liquid mixer and a microprocessor that records biosensor readings. This entire device is encased in protective housing, which includes a container holder. This technology lets the pathogen detection status be obtained remotely in real time using radio frequency identification (RFID) readers.

Source URL (retrieved on *07/28/2014 - 11:26pm*):
http://www.mdtmag.com/news/2013/02/frost-sullivan-acknowledges-pkcs-biosensors-are-expected-become-new-industry-standard-pathogen-testing